scbmtБИОМЕДИЦИНАJournal Biomed2074-59822713-0428Scientific center of biomedical technologies of Federal Medical and Biological Agencyscbmt-639Research ArticleСтатьиМетоды прогнозирования кишечной проницаемости лекарственных веществ с применением компьютерного моделированияШохинИ. Е.noemail@neicon.ruРаменскаяГ. В.ramenskaia@mail.ruПервый московский государственный медицинский университет им. И.М.Сеченова, МоскваRussian Federation201113022020123540Copyright © Шохин И.Е., Раменская Г.В., 20202020Шохин И.Е., Раменская Г.В.Шохин И.Е., Раменская Г.В.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.scbmt.ru/jour/article/view/639

Статья посвящена основным подходам, применяемым для оценки кишечной проницаемости лекар- ственных веществ с использованием компьютерного моделирования (методов in silico). Приведена вза- имосвязь некоторых физико-химических параметров субстанций (log P, C log P, log D) и коэффициен- та кишечной проницаемости, а также достоверность данной корреляции. Описаны основные компью- терные программы, применяемые для прогнозирования проницаемости, и модели, лежащие в основе их функционирования.

абсорбцияпроницаемостькоэффициент распределенияметоды in silicoReferencesAmidon G.L., Lennerlas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability // Pharmaceutical Recearch. - 1995. - № 12. - р. 413-420. 2. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. U.S., Department of Health and Human Services, Food and Drug Administration (HHS-FDA), Center for Drug Evaluation and Research (CDER). - 2000. 3. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. Technical Report Series, No 937, 40th Report, Annex 8 of WHO Expert Committee on Specifications for Pharmaceutical Preparations. World Health Organization (WHO). - 2006. 4. Guidance on the Investigation of Bioequivalence. European Medicines Agency (EMA). Committee for Medicinal Products of Human Use (CHMP). - 2010.Amidon G.L., Lennerlas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability // Pharmaceutical Recearch. - 1995. - № 12. - р. 413-420. 2. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. U.S., Department of Health and Human Services, Food and Drug Administration (HHS-FDA), Center for Drug Evaluation and Research (CDER). - 2000. 3. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. Technical Report Series, No 937, 40th Report, Annex 8 of WHO Expert Committee on Specifications for Pharmaceutical Preparations. World Health Organization (WHO). - 2006. 4. Guidance on the Investigation of Bioequivalence. European Medicines Agency (EMA). Committee for Medicinal Products of Human Use (CHMP). - 2010.Kasim N.A., Whitehouse M., RamachandranC.,BermejoM., Lennernäs H., Hussain A.S., JungingerH.E., Stavchansky S.A., Midha K.K., Shah V.P., Amidon G.L. Molecular properties of WHO essential drugs and provisional biopharmaceuticalclassification// Molecular Pharmaceutics. - 2004. - Vol. 1. - № 1. - р. 85-96.Kasim N.A., Whitehouse M., RamachandranC.,BermejoM., Lennernäs H., Hussain A.S., JungingerH.E., Stavchansky S.A., Midha K.K., Shah V.P., Amidon G.L. Molecular properties of WHO essential drugs and provisional biopharmaceuticalclassification// Molecular Pharmaceutics. - 2004. - Vol. 1. - № 1. - р. 85-96.Kim J.-S., Mitchell S., Kijek P., Tsume Y., Hilfinger J., Amidon G.L. The suitability of an in situ perfusion model for permeability determinations: utility for BCS Class I biowaiver requests // Molecular Pharmaceutics. - 2006. - Vol. 3. - № 6. - р. 686-694.Kim J.-S., Mitchell S., Kijek P., Tsume Y., Hilfinger J., Amidon G.L. The suitability of an in situ perfusion model for permeability determinations: utility for BCS Class I biowaiver requests // Molecular Pharmaceutics. - 2006. - Vol. 3. - № 6. - р. 686-694.Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - Fact or myth // Pharmaceutical Research. - 1997. - Vol. 14. - № 6. - р. 763-766.Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - Fact or myth // Pharmaceutical Research. - 1997. - Vol. 14. - № 6. - р. 763-766.Dahan A., Miller J.M., Amidon G.L. Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World's Top Oral Drugs // AAPS J. - 2009. - Vol. 11. - № 6. - р. 740-746.Dahan A., Miller J.M., Amidon G.L. Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World's Top Oral Drugs // AAPS J. - 2009. - Vol. 11. - № 6. - р. 740-746.Takagi T., Ramachandran C., Bermejo M., Yamashita S., Yu L.X., Amidon G.L.Provisionalbiopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan // Molecular Pharmaceutics. - 2006. - Vol. 3. - № 6. - р. 631-643.Takagi T., Ramachandran C., Bermejo M., Yamashita S., Yu L.X., Amidon G.L.Provisionalbiopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan // Molecular Pharmaceutics. - 2006. - Vol. 3. - № 6. - р. 631-643.Головенко Н.Я., Борисюк Ю.И. Биофармацевтическая классификацион- ная система - экспериментальная мо- дель прогнозирования биодоступности лекарственных средств // Биомедицин- ская химия. - 2008. - Т. 54. - №. 4. - с. 392-407.Головенко Н.Я., Борисюк Ю.И. Биофармацевтическая классификацион- ная система - экспериментальная мо- дель прогнозирования биодоступности лекарственных средств // Биомедицин- ская химия. - 2008. - Т. 54. - №. 4. - с. 392-407.Hansch C., Leo A., Mekapatia S.B., Kurup A. QSAR and ADME // Bioorganic & Medicinal Chemistry. -2004. - № 12. - р. 3391-3400.Hansch C., Leo A., Mekapatia S.B., Kurup A. QSAR and ADME // Bioorganic & Medicinal Chemistry. -2004. - № 12. - р. 3391-3400.Кубиньи Г. В поисках новых соединений-лидеров для создания ле- карств // Российский Химический Жур- нал. - 2006. - Т. 50. - № 2. - с. 5-17.Кубиньи Г. В поисках новых соединений-лидеров для создания ле- карств // Российский Химический Жур- нал. - 2006. - Т. 50. - № 2. - с. 5-17.http://www.biobyte.com/index.html. Проверено 22.03.2011.http://www.biobyte.com/index.html. Проверено 22.03.2011.Benet L., Amidon G.L., Barends D., Lennernäs H., Polli J.E., Shah V.P., Stavchansky S., Yu L. X. Application of BDDCS to Predict Drug Disposition // Pharmaceutical Research. - 2008. - Vol. 52. - № 3. - р. 483-488.Benet L., Amidon G.L., Barends D., Lennernäs H., Polli J.E., Shah V.P., Stavchansky S., Yu L. X. Application of BDDCS to Predict Drug Disposition // Pharmaceutical Research. - 2008. - Vol. 52. - № 3. - р. 483-488.Boobisa A., Gundert-Remyb U., Kremersc P., Macherasd P., Pelkonen O. In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15 // European Journal of Pharmaceutical Sciences. - 2002. - Vol. 17. - р. 183-193.Boobisa A., Gundert-Remyb U., Kremersc P., Macherasd P., Pelkonen O. In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15 // European Journal of Pharmaceutical Sciences. - 2002. - Vol. 17. - р. 183-193.Johansson R., Paterson R. Physiologically based in silico models for the prediction of oral drug absorption. In: Drug absorption studies. In situ, in vitro and in silico models. AAPS Press, NY, USA. - 2008. - P. 486-510.Johansson R., Paterson R. Physiologically based in silico models for the prediction of oral drug absorption. In: Drug absorption studies. In situ, in vitro and in silico models. AAPS Press, NY, USA. - 2008. - P. 486-510.http://www.simulations-plus.com/ Products.aspx?grpID=3&cID=16&pID=11. Проверено 22.03.2011.http://www.simulations-plus.com/ Products.aspx?grpID=3&cID=16&pID=11. Проверено 22.03.2011.

The authors declare that there are no conflicts of interest present.